Biotricity

111 articles with Biotricity

• Biotricity Launches Biocare Telemed for Safe and Convenient Remote Patient CareSecure HIPAA compliant technology for at-risk chronic care patients

  11/12/2020

  Biotricity Inc . (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today introduced Biocare Telemed, a virtual clinic that provides user-friendly access for patients to receive outstanding medical care and remote patient cardiac monitoring from their physician of choice in the safety and comfort of their home. “The arrival of COVID-19 has highlighted the importance of having remote care systems in place

• Biotricity Provides Quarter Update and Announces Continued GrowthTechnology Revenues Surged in the Quarter Ended June 30, 2020

  9/1/2020

  Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced record results in its technology service revenues, demonstrating a continued pattern of improved growth for its first fiscal quarter ending June 30, 2020.

• Biotricity Signs Agreement with Telemedicine CompanyBiotricity is well positioned to provide an integrated telehealth solution combining remote monitoring and telemedicine

  8/12/2020

  Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, today announced that it has entered into an Agreement that establishes terms under which Biotricty will enter into a licensing agreement. Biotricity has negotiated to license, with the exclusive right to acquire MD Matrix and its telemedicine platform that includes real-time streaming of medical devices, making it a perfect fit for th

• Biotricity Receives FDA clearance for Bioflux Software II SystemThe software significantly improves workflows for analysis, increasing efficiency and reducing costs

  8/4/2020

  Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, today announced that it has received a 510(k) clearance from the FDA for its Bioflux Software II System. The software is engineered to improve workflows and reduce analysis time from 5 minutes to 30 seconds. ECG monitoring requires significant human oversight to review and interpret incoming patient data to discern actionable events

• Biotricity® Partners with Verizon to Develop EMS SolutionsVerizon to Integrate the Bioflux® Solution into their EMS and Launch to Existing and Future Customers

  7/14/2020

  Biotricity Inc. (OTCQB: BTCY ), a medical diagnostic and consumer healthcare technology company announced a strategic partnership with Verizon (NYSE: VZ ) to develop EMS solutions for First Responders by integrating its Bioflux solution. Bioflux is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of patients' ECG information. Integrating the Bioflux solution

• Biotricity Shows Continued Growth through its Preliminary Year-End Guidance and Provides Calendar Second Quarter Update

  7/8/2020

  Biotricity Inc. ( OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, today provided guidance on its financial results for the year ended March 31, 2020, announcing that it has experienced increases of approximately 260% in gross annual revenues, year over year, and 113% quarter over quarter. This guidance is being provided in advance of filing audited results within its 10-K, which it anticipates f

• Emerging Markets Report: An Important StepBiotricity Draws Closer to a Critical Binary Moment for the Company

  5/22/2020

  ORLANDO, Fla., May 22, 2020 (GLOBE NEWSWIRE) -- Breaking news last night commemorates a very important step for medical technology company Biotricity (OTCQB: BTCY) . For our many readers following the Company and its investors, today is significant. What is coming for Biotricity is a binary event that could change its future dramatically. Here’s what you need to know. Today, Biotricity reported that it recently received correspondence from the FDA

• Biotricity FDA Submission UpdateBiotricity Moves to the Substantiative Phase of the Review Process.   

  5/20/2020

  Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to announce that it recently received communication from the FDA stating that its 510(k) submission for its next generation Bioflux Software Device is now in the Substantiative Phase of the review process with an expected response by the end of June.

• Biotricity Expands Board of Directors with New AppointmentBiotricity adds Steve Salmon to its Board of Directors, a Serial Entrepreneur and Successful Venture Capitalist with a track record in growing medical companies

  4/30/2020

  Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, announced that Steve Salmon has joined its Board of Directors. Mr. Salmon will bring additional expertise in business development transactions, market development, finance, technology, and capital market. His most recent experience was as a Venture Capitalist for Latterell Venture Partners, where he managed a number of portfolio comp

• One America News (OAN) Interviews Biotricity’s CEO for his Insight into Telemedicine and how Remote Diagnostics can take it FurtherCEO discusses how Biotricity’s technology fits into Telemedicine and helps Expand its Use Cases

  4/23/2020

  Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced that its CEO, Waqaas Al-Siddiq, was recently interviewed on OAN to discuss Telemedicine and how Biotricity and its Bioflux solution can be used to expand the use cases for Telemedicine.

• Biotricity’s CEO Interviewed on Newsmax to discuss Remote Patient Monitoring and TelemedicineCEO discusses how Biotricity’s technology is currently being used to actively monitor and diagnose patients remotely

  4/21/2020

  Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, announced that its CEO, Waqaas Al-Siddiq, was recently interviewed on Newsmax to discuss Remote Patient Monitoring, Telemedicine and how Biotricity and its Bioflux solution is currently being used to remotely monitor patients. “It is exciting and humbling to have the Company and our technology recognized as a leader. Remote Diagnost

• Biotricity’s Real-Time Monitoring Bioflux Device can Help Identify Life Threatening QT Prolongation in COVID-19 Patients

  4/7/2020

  Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that its Bioflux® units are designed for QT interval analysis, a section of the ECG, to identify serious risks like QT prolongation

• Biotricity Issues COVID-19 UpdateCompany to Continue with Normal Operations, Ensures Robust Product Supply for Customers in case of Increased Demand

  3/20/2020

  Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company,  issued a response today to the ongoing COVID-19 impact, reassuring its valued customers, shareholders, and partners that business will continue as usual. The company has taken steps to ensure that its customers have continued access to an increased supply of Bioflux® units as demand for remote patient monitoring grows during this ti

• Biotricity Launches Innovative Pain Management Product with NeuPath HealthCompany Secures First Customer Contract and Expands into the Chronic Care/Pain Management Market

  3/10/2020

  Biotricity Inc. announced that it has launched its innovative pain management product with CPM Centres for Pain Management, a subsidiary of NeuPath Health, Canada’s largest provider of chronic pain management services.

• Legendary Cardiologist and Serial Entrepreneur Dr. John Simpson to Chair Biotricity’s Scientific & Medical Alliance Board

  3/3/2020

  World Renowned Physician and Successful Entrepreneur in Interventional Cardiology Will Provide Valuable Clinical Insights for Product Research and Development

• Emerging Markets Report - Biotricity Soars On Q4 Earnings Growth Tailwinds

  2/20/2020

  ORLANDO, Fla., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Earlier this week, the medical diagnostic and healthcare tech company opened its fourth quarter earnings book covering the three-month period ending December 31, 2019. Here’s what the company revealed in its latest SEC Form 10-Q (which can be found on the company’s investor page ): Biotricity’s net revenue in Q4 showed a year-over-year increase of 224.63%.   Gross revenues earned in Q4 alone is equal to 96% of the gross revenues that had

• Biotricity Posts Calendar Q4 Results that Show Continued Growth

  2/18/2020

  Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced calendar fourth quarter financial results for the three months which ended December 31, 2019.

• Biotricity Converts $1.8 Million of Private Investor Notes into Preferred EquityA Cumulative $7.8 Million Raised Thus Far to be Used to Expand Sales and Strengthen the Product Offering of its Proprietary Remote Monitoring Platform

  1/7/2020

  Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has converted approximately $1.8 million in debt investment from long-term private investors into its recent Preferred Equity transaction, bringing the cumulative total sold in this round to $7.8 million.

• Emerging Markets Report: An Ounce of Prevention

  12/23/2019

  An Emerging Markets News Commentary

• Biotricity Completes $6M Investment from Private InvestorCompany Prepares for Sales and Product Expansion

  12/19/2019

  Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced that it has completed a $6M investment from its long term Private Investor in the form of a Preferred Equity transaction.